Humacyte Inc
NASDAQ:HUMA
Intrinsic Value
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of HUMA.
Humacyte Inc's market capitalization is 446.8m USD.
HUMA stock price is 3.82 USD.
HUMA.
HUMA. Open DCF Valuation
HUMA. Open Relative Valuation
HUMA has upside potential of 100% compared to the average analyst price target.
Open Wall St Estimates
HUMA's long-term assets (128m USD) exceed its long-term liabilties (115m USD).
HUMA's D/E (Debt to Equity) is equal to 1.2.
HUMA has negative Operating Income for the last twelve months.
HUMA has negative Net Income for the last twelve months.
HUMA's ROE (Return on Equity) for the past 12 months is negative and is equal to -170%.
HUMA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -217%.
HUMA has negative Free Cash Flow for the last twelve months.
HUMA has negative three-year average ROE (Return on Equity): -62%. The company is not efficient at transforming stockholders' equity into net income.
HUMA has negative three-year average ROIC (Return on Invested Capital): -157%. The company is not efficient at using invested capital to generate operating income.
HUMA's short-term assets (83m USD) exceed its short-term liabilties (18m USD).
HUMA has negative Net Debt. This means that the company has more cash and short-term investments (80m USD) than debt (16m USD).
HUMA's Altman Z-Score is very low and is equal to -6.85.
HUMA doesn't generate enough operating income (-100m USD) to safely cover interest payments on its debt (2m USD).
Fundamental Analysis
Humacyte Inc
Balance Sheet Decomposition
Humacyte Inc
| Current Assets | 83.3m |
| Cash & Short-Term Investments | 80.4m |
| Other Current Assets | 2.8m |
| Non-Current Assets | 44.9m |
| PP&E | 44.7m |
| Other Non-Current Assets | 241k |
| Current Liabilities | 18.4m |
| Accounts Payable | 6.5m |
| Accrued Liabilities | 9.4m |
| Other Current Liabilities | 2.6m |
| Non-Current Liabilities | 96.2m |
| Long-Term Debt | 16.3m |
| Other Non-Current Liabilities | 79.9m |
Earnings Waterfall
Humacyte Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-100m
USD
|
|
Operating Income
|
-100m
USD
|
|
Other Expenses
|
-10.7m
USD
|
|
Net Income
|
-110.8m
USD
|
Free Cash Flow Analysis
Humacyte Inc
HUMA Profitability Score
Profitability Due Diligence
Humacyte Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Humacyte Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
HUMA Solvency Score
Solvency Due Diligence
Humacyte Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Humacyte Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HUMA Price Targets Summary
Humacyte Inc
According to Wall Street analysts, the average 1-year price target for
HUMA
is 7.65 USD
with a low forecast of 4.04 USD and a high forecast of 15.75 USD.
Ownership
HUMA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
HUMA Price
Humacyte Inc
| Average Annual Return | -49.44% |
| Standard Deviation of Annual Returns | 31.19% |
| Max Drawdown | -88% |
| Market Capitalization | 446.8m USD |
| Shares Outstanding | 116 975 000 |
| Percentage of Shares Shorted | 5.07% |
Company Profile
Humacyte Inc
Country
Industry
Market Cap
Dividend Yield
Description
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
You don't have any saved screeners yet
